NO20041891L - Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer - Google Patents
Amidderivater som glykogensyntase-kinase 3beta-inhibibitorerInfo
- Publication number
- NO20041891L NO20041891L NO20041891A NO20041891A NO20041891L NO 20041891 L NO20041891 L NO 20041891L NO 20041891 A NO20041891 A NO 20041891A NO 20041891 A NO20041891 A NO 20041891A NO 20041891 L NO20041891 L NO 20041891L
- Authority
- NO
- Norway
- Prior art keywords
- hydrogen
- optionally substituted
- nhc
- alkenyl
- amino
- Prior art date
Links
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
Denne oppfinnelse vedrører en forbindelse med formel. et N-oksid, et farmasøytisk akseptabelt addisjonssalt, et kvaternært amin og en stereokjemisk isomer form derav, hvori ring A representerer en 6-leddet heterocykel; Rer hydrogen; aryl; formyl; Calkylkarbonyl; eventuelt substituert Calkyl; Ci^alkyloksykarbonyl; eventuelt substituert CalkyloksyCalkylkarbonyl; X er en direktebinding eller et linkeratom eller gruppe; Z er O eller S; Rer hydrogen, C.oalkyl, C-alkenyl, C-alkynyl, en karbocykel eller en heterocykel, hyer av gruppene kan eventuelt vaste substituert; Rer hydrogen; hydroksy; halo; eventuelt substituert Calkyl eller C-alkenyl eller Calkynyl; Calkyloksy; Calkyltio; Calkyloksy-karbonyl; Calkylkarbonyloksy; karboksyl; cyano; nitro; amino; mono- eller di(C.alkyl)amino; polyhaloCalkyl; polyhaloCalkyloksy; polyhaloCalkyltio; RCalkyl; R0-; RS-; R(0)-; RS(=0)p-; RS(=0)p-;. RS(=0)p-NH-; RS(=0)p-NH-; RC(=0)-; -NHC(=0)H; -C(=0)NHNH; RC(=0)-NHC(=0)-NH-; -C(=NH)R; -C(=NH)R; Reller Rrepresenterer hver uavhengig hydrogen, R, -Y-NRY-NRR'', -Y,-NR'-Y-R', -Y-NRV; forutsatt at -X-Rog/eller Rer forskjellig fra hydrogen; deres anvendelse, farma-søytiske sammensetninger omfattende dem og fremgangsmåter for deres fremstilling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01204193 | 2001-11-01 | ||
PCT/EP2002/012067 WO2003037869A1 (en) | 2001-11-01 | 2002-10-29 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20041891L true NO20041891L (no) | 2004-05-07 |
NO327097B1 NO327097B1 (no) | 2009-04-20 |
Family
ID=8181176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041891A NO327097B1 (no) | 2001-11-01 | 2004-05-07 | Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer |
Country Status (21)
Country | Link |
---|---|
US (1) | US7183288B2 (no) |
EP (1) | EP1442019B8 (no) |
JP (1) | JP2005507419A (no) |
KR (1) | KR20050040814A (no) |
CN (1) | CN1582277A (no) |
AT (1) | ATE375331T1 (no) |
AU (1) | AU2002363174B2 (no) |
BR (1) | BR0213791A (no) |
CA (1) | CA2463821A1 (no) |
DE (1) | DE60222921T2 (no) |
DK (1) | DK1442019T3 (no) |
EA (1) | EA007578B1 (no) |
ES (1) | ES2294190T3 (no) |
HU (1) | HUP0402330A3 (no) |
IL (1) | IL161661A0 (no) |
MX (1) | MXPA04004177A (no) |
NO (1) | NO327097B1 (no) |
NZ (1) | NZ531855A (no) |
PL (1) | PL368917A1 (no) |
PT (1) | PT1442019E (no) |
WO (1) | WO2003037869A1 (no) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2506415A1 (en) | 2002-11-19 | 2004-06-03 | Achillion Pharmaceuticals, Inc. | Substituted aryl thioureas and releated compounds; inhibitors of viral replication |
EP1761496A2 (en) | 2004-03-31 | 2007-03-14 | Janssen Pharmaceutica N.V. | Non-imidazole heterocyclic compounds as histamine h3-receptor ligands |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
WO2006000589A1 (en) | 2004-06-28 | 2006-01-05 | Altana Pharma Ag | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CA2633740A1 (en) * | 2005-12-22 | 2007-06-28 | Crystalgenomics, Inc. | Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
CA2653940C (en) | 2006-05-30 | 2015-07-14 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
MX2009010363A (es) | 2007-03-28 | 2009-12-04 | Abbott Lab | Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide. |
US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) * | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
UA103468C2 (ru) | 2007-11-20 | 2013-10-25 | Янссен Фармацевтика Н.В. | Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3 |
FR2931108B1 (fr) * | 2008-05-15 | 2011-01-07 | Peugeot Citroen Automobiles Sa | Limiteur de vitesse a indicateur de vitesse limite a deplacement manuel, pour vehicule automobile |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
WO2010033543A2 (en) * | 2008-09-16 | 2010-03-25 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
PA8854001A1 (es) * | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
JP5940984B2 (ja) | 2010-01-22 | 2016-06-29 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法 |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
ES2568260T3 (es) | 2010-11-16 | 2016-04-28 | Acetylon Pharmaceuticals, Inc. | Compuestos de pirimidin hidroxi amida como inhibidores de proteína desacetilasa y métodos de uso de los mismos |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
CN103804362A (zh) * | 2012-11-12 | 2014-05-21 | 韩文毅 | 一类治疗糖尿病的化合物及其用途 |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3054952B1 (en) | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
US9278963B2 (en) | 2013-10-10 | 2016-03-08 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
WO2015061684A1 (en) | 2013-10-24 | 2015-04-30 | Mayo Foundation For Medical Education And Research | Treatment of polycystic diseases with an hdac6 inhibitor |
BR112016012561A2 (pt) | 2013-12-03 | 2017-08-08 | Acetylon Pharmaceuticals Inc | Combinações de inibidores da histona desacetilase e fármacos imunomoduladores |
US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
US9833466B2 (en) | 2014-07-07 | 2017-12-05 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
EP3303304B1 (en) | 2015-06-08 | 2019-11-20 | Acetylon Pharmaceuticals, Inc. | Methods of making protein deacetylase inhibitors |
AR104935A1 (es) | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
WO2018031472A1 (en) | 2016-08-08 | 2018-02-15 | Acetylon Pharmaceuticals Inc. | Pharmaceutical combinations of histone deacetylase 6 inhibitors and cd20 inhibitory antibodies and uses thereof |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
CN110128305A (zh) * | 2019-05-10 | 2019-08-16 | 天津大学 | 二甲双胍-甲苯磺丁脲新盐型、其制备方法及医药用途 |
CN116813497B (zh) * | 2023-08-31 | 2023-11-14 | 天津匠新致成科技有限公司 | 一种酰胺类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1198551A (en) | 1968-01-22 | 1970-07-15 | Union Pharma Scient Appl | New Nicotinuric Acid Derivatives |
GB1401549A (en) | 1972-07-07 | 1975-07-16 | Hisamitsu Pharmaceutical Co | Pyrido-2,3-d-pyrimidine-2,4-1h,3h- diones and methods of preparing them |
JPS5069096A (no) | 1973-10-25 | 1975-06-09 | ||
US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
NO311614B1 (no) | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
EP1054004B1 (en) * | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
HU230522B1 (hu) | 1998-03-27 | 2016-10-28 | Janssen Pharmaceutica N.V | HIV-gátló pirimidinszármazékok |
EP1087963B1 (en) * | 1998-06-19 | 2004-08-25 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
RU2260592C9 (ru) | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Циклические ингибиторы протеинтирозинкиназ |
-
2002
- 2002-10-29 BR BR0213791-7A patent/BR0213791A/pt not_active IP Right Cessation
- 2002-10-29 US US10/493,454 patent/US7183288B2/en not_active Expired - Fee Related
- 2002-10-29 WO PCT/EP2002/012067 patent/WO2003037869A1/en active IP Right Grant
- 2002-10-29 HU HU0402330A patent/HUP0402330A3/hu unknown
- 2002-10-29 DE DE60222921T patent/DE60222921T2/de not_active Expired - Lifetime
- 2002-10-29 IL IL16166102A patent/IL161661A0/xx unknown
- 2002-10-29 AU AU2002363174A patent/AU2002363174B2/en not_active Ceased
- 2002-10-29 EA EA200400615A patent/EA007578B1/ru not_active IP Right Cessation
- 2002-10-29 PT PT02790304T patent/PT1442019E/pt unknown
- 2002-10-29 JP JP2003540151A patent/JP2005507419A/ja active Pending
- 2002-10-29 KR KR1020047004827A patent/KR20050040814A/ko active IP Right Grant
- 2002-10-29 NZ NZ531855A patent/NZ531855A/en not_active IP Right Cessation
- 2002-10-29 AT AT02790304T patent/ATE375331T1/de active
- 2002-10-29 CA CA002463821A patent/CA2463821A1/en not_active Abandoned
- 2002-10-29 EP EP02790304.6A patent/EP1442019B8/en not_active Expired - Lifetime
- 2002-10-29 CN CNA028219171A patent/CN1582277A/zh active Pending
- 2002-10-29 PL PL02368917A patent/PL368917A1/xx not_active Application Discontinuation
- 2002-10-29 MX MXPA04004177A patent/MXPA04004177A/es active IP Right Grant
- 2002-10-29 ES ES02790304T patent/ES2294190T3/es not_active Expired - Lifetime
- 2002-10-29 DK DK02790304T patent/DK1442019T3/da active
-
2004
- 2004-05-07 NO NO20041891A patent/NO327097B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60222921T2 (de) | 2008-08-07 |
CA2463821A1 (en) | 2003-05-08 |
EA007578B1 (ru) | 2006-12-29 |
JP2005507419A (ja) | 2005-03-17 |
EP1442019B8 (en) | 2013-10-30 |
DK1442019T3 (da) | 2008-01-14 |
ES2294190T3 (es) | 2008-04-01 |
HUP0402330A2 (hu) | 2005-02-28 |
US20050176713A1 (en) | 2005-08-11 |
ATE375331T1 (de) | 2007-10-15 |
BR0213791A (pt) | 2004-12-07 |
MXPA04004177A (es) | 2004-09-06 |
DE60222921D1 (de) | 2007-11-22 |
EA200400615A1 (ru) | 2004-08-26 |
HUP0402330A3 (en) | 2010-03-29 |
PT1442019E (pt) | 2007-12-11 |
EP1442019B1 (en) | 2007-10-10 |
PL368917A1 (en) | 2005-04-04 |
WO2003037869A1 (en) | 2003-05-08 |
NZ531855A (en) | 2005-12-23 |
KR20050040814A (ko) | 2005-05-03 |
AU2002363174B2 (en) | 2008-09-25 |
EP1442019A1 (en) | 2004-08-04 |
US7183288B2 (en) | 2007-02-27 |
CN1582277A (zh) | 2005-02-16 |
NO327097B1 (no) | 2009-04-20 |
IL161661A0 (en) | 2004-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20041891L (no) | Amidderivater som glykogensyntase-kinase 3beta-inhibibitorer | |
NO20041911L (no) | Heteroarylaminer som glykogensyntase-kinase 3beta-inhibitorer (GSK3-inhibitorer) | |
MXPA04004176A (es) | Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa. | |
NO20073823L (no) | Kinolinderivater for behandlingen av latent tuberkulose | |
NO20080955L (no) | Kinolinderivater som antibakterielle midler | |
TW200642683A (en) | Heterocyclic compound | |
MY101359A (en) | 7-acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them, their starting compounds and their preparation | |
SG166019A1 (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
AR053784A1 (es) | Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas. | |
TW200736232A (en) | Pyrimidine derivatives | |
MX2012001420A (es) | Derivados de pirrolo[1,2-b]piridazina como inhibidores de cinasa janus. | |
ATE259803T1 (de) | 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung | |
SG155946A1 (en) | Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | |
MXPA04002495A (es) | Compuestos de imidazopiridin como moduladores del receptor 5-ht4. | |
WO2008110690A3 (fr) | Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens | |
CY1110950T1 (el) | Ενωσεις ιμιδαζολιδινονυλ αμινοπυριμιδινης για τη θεραπευτικη αντιμετωπιση του καρκινου | |
TW200606154A (en) | Mercaptoimidazoles as CCR2 receptor antagonists | |
NO20022758D0 (no) | Fremgangsmåte for fremstilling av aryletanolaminderivater med antifedme og antidiabetiske egenskaper | |
UA88766C2 (ru) | Производные хинолина для лечения латентного туберкулеза | |
MY139783A (en) | Mercaptoimidazoles as ccr2 receptor antagonists | |
GB0325644D0 (en) | Immuno ihibitory pyrazolone compounds | |
EP1344777A4 (en) | IMIDAZOLE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR APPLICATION | |
MX2008011216A (es) | 1,5-dihidro-imidazol-2-onas 4-amino-1,5-substituidas. | |
MX2012006897A (es) | Compuestos heterociclicos como inhibidores de janus cinasa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |